Myriad Genetics (MYGN) Metrics: History & Chart

Myriad Genetics, Inc.(MYGN)

Medical - Diagnostics & Research · Salt Lake City, UT

$4.27-0.32 (-6.88%)

Delayed quote: Oct 6, 2026, 11:45 AM EDT

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Salt Lake City, UT

2,700 employees

www.myriad.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Samraat S. Raha

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+8.02%
30D Total Return	+43.57%
YTD Total Return	-25.53%
1Y Total Return	-43.18%
3Y Total Return	-70.43%
5Y Total Return	-85.48%
10Y Total Return	-78.37%
15Y Total Return	-76.64%
20Y Total Return	-60.02%

2026	-25.53%
2025	-55.14%
2024	-28.37%
2023	+31.91%
2022	-47.43%
2021	+39.61%
2020

CAGR TTM	-43.02%
CAGR 3Y	-33.37%
CAGR 5Y	-32.02%
CAGR 10Y	-14.20%
CAGR 15Y	-9.24%
CAGR 20Y	-4.48%

PE Ratio	385.45
PE Ratio Avg TTM	75.75
PE Ratio Avg 3Y	51.98
Current VS TTM Avg	+408.86%
Current VS 3Y Avg	+641.47%
Current VS 5Y Avg	+857.52%

All Metrics

MYGN Valuation Metrics

MYGN Stock Price Metrics

MYGN Dividend Metrics

MYGN Growth Rate Metrics

MYGN Discounted Cash Flow Metrics

MYGN Returns By Period

MYGN Yearly Returns

MYGN Average Annual Returns By Period (CAGR)

MYGN Revenue Metrics

MYGN PE Ratio Metrics

MYGN PS Ratio Metrics

MYGN PB Ratio Metrics

MYGN Price to Free Cash Flow Ratio Metrics

MYGN Debt to Equity Ratio Metrics

MYGN PEG Ratio Metrics

MYGN FCF Yield

MYGN Earnings Yield

MYGN EBITDA Yield

MYGN OCF Yield

MYGN EV/EBIT Ratio Metrics

MYGN EV/EBITDA Ratio Metrics

MYGN EV/Assets Ratio Metrics

MYGN EV/Sales Ratio Metrics

MYGN Current Ratio Metrics

MYGN Quick Ratio Metrics

MYGN ROIC Metrics

MYGN Return on Assets Metrics

MYGN Return on Equity Metrics

MYGN Net Profit Margin Metrics

MYGN Gross Profit Margin Metrics

MYGN Tax Rate Metrics

PS Ratio	0.54
PS Ratio Avg TTM	0.60
PS Ratio Avg 3Y	1.42
Current VS TTM Avg	-9.54%
Current VS 3Y Avg	-62.01%
Current VS 5Y Avg	-72.78%

PB Ratio	1.43
PB Ratio Avg TTM	1.38
PB Ratio Avg 3Y	1.80
Current VS TTM Avg	+3.38%
Current VS 3Y Avg	-20.69%
Current VS 5Y Avg	-21.50%

PFCF Ratio	8585.25
PFCF Ratio Avg TTM	4285.33
PFCF Ratio Avg 3Y	23.26
Current VS TTM Avg	+100.34%
Current VS 3Y Avg	+36811.09%
Current VS 5Y Avg	+37336.73%

Debt/Equity Ratio	0.69
Debt/Equity Ratio Avg TTM	0.57
Debt/Equity Ratio Avg 3Y	0.36
Current VS TTM Avg	+21.20%
Current VS 3Y Avg	+94.51%
Current VS 5Y Avg	+257.63%

PEG Ratio	273.94
PEG Ratio Avg TTM	116.35
PEG Ratio Avg 3Y	116.35
Current VS TTM Avg	+135.44%
Current VS 3Y Avg	+135.44%
Current VS 5Y Avg	+376.18%

FCF Yield	0.01%
FCF Yield Avg TTM	0.27%
FCF Yield Avg 3Y	3.53%
Current VS TTM Avg	-96.33%
Current VS 3Y Avg	-99.72%
Current VS 5Y Avg	-99.78%

Earnings Yield	0.26%
Earnings Yield Avg TTM	0.81%
Earnings Yield Avg 3Y	2.85%
Current VS TTM Avg	-68.08%
Current VS 3Y Avg	-90.89%
Current VS 5Y Avg	-92.14%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	224.46
Ev/Ebit Ratio Avg TTM	102.82
Ev/Ebit Ratio Avg 3Y	41.04
Current VS TTM Avg	+118.31%
Current VS 3Y Avg	+446.87%
Current VS 5Y Avg	+1071.09%

Ev/Ebitda Ratio	30.16
Ev/Ebitda Ratio Avg TTM	30.26
Ev/Ebitda Ratio Avg 3Y	22.88
Current VS TTM Avg	-0.33%
Current VS 3Y Avg	+31.82%
Current VS 5Y Avg	+61.79%

Ev/Assets Ratio	0.83
Ev/Assets Ratio Avg TTM	0.82
Ev/Assets Ratio Avg 3Y	1.20
Current VS TTM Avg	+1.03%
Current VS 3Y Avg	-30.63%
Current VS 5Y Avg	-35.50%

Ev/Sales Ratio	0.66
Ev/Sales Ratio Avg TTM	0.69
Ev/Sales Ratio Avg 3Y	1.51
Current VS TTM Avg	-4.33%
Current VS 3Y Avg	-56.20%
Current VS 5Y Avg	-67.31%

Current Ratio	2.21
Current Ratio Avg TTM	2.17
Current Ratio Avg 3Y	1.92
Current VS TTM Avg	+1.88%
Current VS 3Y Avg	+14.87%
Current VS 5Y Avg	+5.44%

Quick Ratio	1.98
Quick Ratio Avg TTM	1.96
Quick Ratio Avg 3Y	1.80
Current VS TTM Avg	+0.69%
Current VS 3Y Avg	+9.78%
Current VS 5Y Avg	+1.59%

ROIC	(19.13%)
ROIC Avg 3Y	(36.42%)
ROIC Avg 5Y	(17.39%)
Current VS 3Y Avg	+47.48%
Current VS 5Y Avg	-9.98%
Current VS 10Y Avg	-140.60%

ROA	(17.62%)
ROA Avg TTM	(13.10%)
ROA Avg 3Y	(3.87%)
Current VS TTM Avg	-34.50%
Current VS 3Y Avg	-355.17%
Current VS 5Y Avg	-492.93%

ROE	(37.05%)
ROE Avg TTM	(92.85%)
ROE Avg 3Y	(51.69%)
Current VS TTM Avg	+60.10%
Current VS 3Y Avg	+28.33%
Current VS 5Y Avg	-111.70%

Net Profit Margin	(13.96%)
Net Profit Margin Avg TTM	(42.37%)
Net Profit Margin Avg 3Y	(15.03%)
Current VS TTM Avg	+67.05%
Current VS 3Y Avg	+7.14%
Current VS 5Y Avg	+6.69%

Gross Profit Margin	68.83%
Gross Pft Margin Avg TTM	69.27%
Gross Pft Margin Avg 3Y	69.35%
Current VS TTM Avg	-0.64%
Current VS 3Y Avg	-0.75%
Current VS 5Y Avg	-1.27%

Tax Rate	38.19%
Tax Rate Avg 3Y	39.22%
Tax Rate Avg 5Y	33.90%
Current VS 3Y Avg	-2.62%
Current VS 5Y Avg	+12.67%
Current VS 10Y Avg	+2.74%